Researchers at Regentis Biomaterials have developed an investigational implant called GelrinC, which is being evaluated as a treatment to help the body regrow cartilage in the knee.
GelrinC is composed of a synthetic material called polyethylene glycol (PEG) and a structurally modified form of human fibrinogen, a protein which in its native form assists healing processes. PEG and native human fibrinogen have been used individually in medical products for many years with excellent results.
GelrinC‘s unique mode of action relies upon its ability to be implanted as a liquid so that it completely fills the defect, and then be cured into a gel that enables the body‘s own stem cells to settle on its surface. Over a period of six to 12 months, the GelrinC is gradually resorbed by the body and replaced by new cartilage tissue.
Preliminary clinical studies in Europe have indicated that this regenerated tissue provides excellent improvement in pain and function.
As part of the standard microfracture procedure, GelrinC is applied to the cartilage defect as a liquid and is then exposed to UVA light for 90 seconds. As a result, it turns into a solid, soft implant, completely occupying the space of the defect.
Watch this video to find out more about the GelrinC procedure.
The table below shows how GelrinC compares to other surgical interventions for the treatment of cartilage damage.
|Suitable for All Lesions||No||No||Yes|
|Number of Surgical Procedures||2||1||1|
|Requires Removal of Healthy Cartilage||Yes||Yes||No|
|Requires Advanced Planning||Yes
|Procedure Time||1-3 hours||15-45 mins||10 min add-on
|Return to daily activities||4-5 months||6-8 weeks||6-8 weeks|